Henagliflozin
- Generic Name
- Henagliflozin
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24ClFO7
- CAS Number
- 1623804-44-3
- Unique Ingredient Identifier
- 21P2M98388
- Background
Henagliflozin has been used in trials studying the treatment of Type 2 Diabetes.
Henagliflozin's Impact on Prediabetes Remission
Phase 4
Not yet recruiting
- Conditions
- Type 2 DiabetesGlucose Metabolism DisordersPrediabetic StatePreDiabetes
- Interventions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Shandong Provincial Hospital
- Target Recruit Count
- 984
- Registration Number
- NCT06448130
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guanzhou, Guangdong, China
🇨🇳First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳Southern Medical University, Guangzhou, Guangdong, China
Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease
Phase 4
Not yet recruiting
- Conditions
- Type 2 DiabetesNon-Alcoholic Fatty Liver Disease
- Interventions
- Other: Background medication
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Sir Run Run Shaw Hospital
- Target Recruit Count
- 156
- Registration Number
- NCT06218342
Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes
Phase 4
Not yet recruiting
- Conditions
- ObeseWeight LossPre-diabetes
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 300
- Registration Number
- NCT06216340
Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Qian geng
- Target Recruit Count
- 240
- Registration Number
- NCT06187727
- Locations
- 🇨🇳
Chinese PLA general hospital, Beijing, Beijing, China
Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical Trial
Not Applicable
Recruiting
- Conditions
- Type 2 Diabetes MellitusMild Cognitive Impairment
- Interventions
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Target Recruit Count
- 60
- Registration Number
- NCT06085703
- Locations
- 🇨🇳
Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University, Nanjing, Jiangsu, China
The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics
Not Applicable
Not yet recruiting
- Conditions
- Sodium-glucose Co-transporter-2 InhibitorMagnetic Resonance ImagingObesityType 2 DiabetesMyocardial Fibrosis
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 64
- Registration Number
- NCT06059287
Henagliflozin Delays the Progress of Diabetic Nephropathy Via Regulates Gut-Renal Axis
Not Applicable
Not yet recruiting
- Conditions
- Diabetic Nephropathies
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Qianfoshan Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT06031389
Effect of Henagliflozin on Cardiac Function in Type 2 Diabetes Patients With Chronic Heart Failure (HERO-HF)
Not Applicable
Recruiting
- Conditions
- Heart Failure
- Interventions
- Drug: blank control
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 1932
- Registration Number
- NCT05742230
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM
Phase 4
Completed
- Conditions
- Type2diabetes
- Interventions
- Device: Continuous Subcutaneous Insulin Infusion
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- First Affiliated Hospital of Guangxi Medical University
- Target Recruit Count
- 210
- Registration Number
- NCT05677334
- Locations
- 🇨🇳
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Henagliflozin in Patients With Atrial Fibrillation
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2022-05-23
- Lead Sponsor
- Beijing Anzhen Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05252624
- Locations
- 🇨🇳
Beijing Anzhen Hospital, Capital Medical University, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath